Study | No. of patients | Radiation technology | Radiation dose (Gy) | Adverse events according to CTCAE grade (No. of patients) | ||
---|---|---|---|---|---|---|
Median | Range | Per fx (no. of fx) | ||||
Aghi et al. [44] | 8 | NR | 60.2†| 59.4–61.2 | 1.5–1.8 | Grade 4 radiation necrosis (n = 1) |
Komotar et al. [9] | 13 | NR | 59.4 | NR | 1.8–2.0 | Grade 1–2 skin dermatitis, erythema, alopecia, fatigue, and headache (NR) |
Park et al. [10] | 17 + 10* | Conventional RT/ 3D-CRT | 61.2 | 40.0–61.2 | NR (30–35) | Grade 1–2 fatigue, headache, nausea, dizziness, skin irritation (NR) |
Aizer et al. [11] | 18 + 12* | NR | 60.0 | 55.8–64.0 | NR | Grade 4 radiation related glioblastoma (n = 1) |
Sun et al. [45] | 39 | NR | 53.8 | 46.0–60.0 | 1.7–2.0 | Grade 1–2 radiation necrosis (n = 1) Grade 4 radiation necrosis (n = 3) |
Wang et al. [26] | 3 + 9* | NR | NR | 54.0–60.0 | NR (27–30) | Grade 1–2 headache, dizziness, and skin irritation (NR) |
Bagshaw et al. [13] | 12 + 9* | NR | 54.0 | 45.0–59.4 | NR | Grade 1 fatigue, headache, and seizure (n = 4) Grade 2 headache, dizziness, alopecia, and hearing and memory impairment (n = 4) Grade 3 radiation necrosis (n = 2) Grade 4 optic nerve disorder (n = 1) |
Graffeo et al. [14] | 8 | NR | 54.0 | 50.5–61.2 | NR (28–30) | Undetermined grade major morbidity (n = 1) |
Dohm et al. [34] | 12 + 51* | 3D-CRT | 55.7 | 50.4–59.4 | NR (28–35) | Grade 4 seizure (n = 1) Grade 3 radiation necrosis, cognitive disturbance, peripheral neuropathy, seizure, aphasia, and optic nerve disorders (n = 7) |
Cho et al. [33] | 13 + 21* | Conventional RT | NR | 30.0–61.2 | NR (30–35) | Grade 1–2 fatigue, headache, nausea, dizziness, and skin irritation (NR) |
Shakir et al. [36] | 12 + 3* | 3D-CRT | 54.0 | 52.2–59.4 | 1.8 | Grade 1–2 headache, dizziness, and paresthesia (n = 8) |
Lee et al. [16] | 20 + 33* | 3D-CRT/IMRT | 50.4/54.0 | 36.0–64.0/50.4–59.4 | 1.8–2.0 | Grade 1 radiation necrosis (n = 2) |
Ros-Sanjuan et al. [38] | 5 + 8* | 3D-CRT | NR | NR | NR | Undetermined grade radiation necrosis (n = 1) |